Aug 26, 2020 / NTS GMT
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello, and welcome to the BioSyent Inc. Q2 and First Half 2020 Results Presentation. My name is René Goehrum , and I'm the President and CEO of the company. After drawing your attention to our forward-looking statements disclaimer, I want to start the presentation with a look at our revenue, EBITDA and net income after tax.
We'll start with a look at the quarter. As you can see, our sales were just below $4.8 million. That was a decline of 7% versus year ago, and this was impacted by a fair amount of trade loading and forward purchasing by our pharmaceutical customers in Canada, pharmacies and, in fact, patients. So the effect was strong accumulation and sales for us in first quarter, and it had a down effect on our revenue in April. We've seen -- subsequent to that, our business has smoothed out and the impact of a big March and a lower April has evened out, and we'll walk through that in a couple of slides.
So this represented our 40th consecutive profitable quarter, 10 years of continuous profitability. We
Q2 2020 Biosyent Inc Earnings Call Transcript
Aug 26, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers